keyword
MENU ▼
Read by QxMD icon Read
search

Loop diuretic, heart failure

keyword
https://www.readbyqxmd.com/read/29332911/impact-of-continuous-administration-of-tolvaptan-on-preventing-medium-term-worsening-renal-function-and-long-term-adverse-events-in-heart-failure-patients-with-chronic-kidney-disease
#1
Yusuke Nakano, Tomofumi Mizuno, Toru Niwa, Kentaro Mukai, Hirokazu Wakabayashi, Atsushi Watanabe, Hirohiko Ando, Hiroaki Takashima, Kenta Murotani, Katsuhisa Waseda, Tetsuya Amano
Tolvaptan (TLV) has an inhibiting effect for worsening renal function (WRF) in acute decompensated heart failure (HF) patients. However, there are limited data regarding the effect of continuous TLV administration on medium-term WRF.This was a retrospective observational study in hospitalized HF patients with chronic kidney disease (CKD). TLV was administered to those patients with fluid retention despite standard HF therapy. We compared 34 patients treated with TLV (TLV group) to 33 patients treated with conventional HF therapy with high-dose loop diuretics (furosemide ≥ 40 mg) (Loop group)...
January 15, 2018: International Heart Journal
https://www.readbyqxmd.com/read/29319788/relationship-of-loop-diuretic-use-with-exercise-intolerance-in-heart-failure-with-preserved-ejection-fraction
#2
David Montero, Thomas Haider
No abstract text is available yet for this article.
January 8, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29318651/effect-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-on-pharmacokinetics-and-pharmacodynamics-of-a-single-dose-of-furosemide
#3
Surya Ayalasomayajula, Uwe Schuehly, Parasar Pal, Fabian Chen, Wei Zhou, Gangadhar Sunkara, Thomas H Langenickel
AIMS: Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be co-administrated with sacubitril/valsartan in clinical practice. The effect of sacubitril/valsartan on pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two- period, single-sequence study in healthy subjects (N=28). METHODS: All subjects received 40 mg oral single dose furosemide during period 1 followed by washout of 2 days...
January 9, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29318439/mind-the-gap-mismatches-between-clinicians-and-patients-in-heart-failure-medication-management
#4
Ken Lee Chin, Marina Skiba, Christopher M Reid, Andrew Tonkin, Ingrid Hopper, Justin A Mariani, Danny Liew
PURPOSE: Previous studies on the 'treatment gap' in patients with heart failure (HF) have focused either on prescribing or patients' adherence to prescribed treatment. This study sought to determine whether or not recent initiatives to close the gap have also minimised any mismatches between physicians' expectation of their patients' medications, medications in the patients' possession and their actual medication use. METHODS: A cross-sectional observational survey was conducted from December 2015 to June 2016 in The Alfred Hospital HF clinic in Melbourne, Australia...
January 9, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29310997/neurohormonal-imbalance-a-neglected-problem-and-potential-therapeutic-target-in-acute-heart-failure
#5
Steven R Goldsmith, Bradley A Bart, Ileana L Piña
Decompensated or acute heart failure (AHF) is characterized by increased ventricular and atrial pressures which may lead to and be caused by circulatory congestion. Unless due to a primary decrease in cardiac function, congestion arises from volume expansion or vasoconstriction. In turn, volume expansion and vasoconstriction are due to neurohormonal imbalance since both result from activation of the sympathetic nervous system, the renin-angiotensin-aldosterone axis and excess secretion of arginine vasopressin...
December 16, 2017: Current Problems in Cardiology
https://www.readbyqxmd.com/read/29226820/furosemide-reimagined-novel-subcutaneous-formulation-for-a-50-year-old-loop-diuretic-agent-for-the-treatment-of-acute-decompensated-heart%C3%A2-failure
#6
EDITORIAL
Gary S Francis, Tamas Alexy
No abstract text is available yet for this article.
November 27, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/29223430/rational-and-design-of-a-randomized-double-blind-multicenter-trial-to-evaluate-the-safety-and-tolerability-of-furosemide-withdrawal-in-stable-chronic-outpatients-with-heart-failure-the-rebic-1-trial
#7
RANDOMIZED CONTROLLED TRIAL
Priscila Raupp da Rosa, Luis E Rohde, Madeni Doebber, Antonio L P Ribeiro, Deborah P Prado, Eduardo G Bertoldi, Jose A Figueiredo Neto, Ilmar Kohler, Luis Beck-da-Silva, Luiz C Danzmann, Lidia Zytynski Moura, Marciane Rover, Marcus V Simões, Roberto T Sant'Anna, Andréia Biolo
AIMS: Furosemide is commonly prescribed for symptom relief in heart failure (HF) patients. Although few data support the continuous use of loop diuretics in apparently euvolemic HF patients with mild symptoms, there is concern about safety of diuretic withdrawal in these patients. The ReBIC-1 trial was designed to evaluate the safety and tolerability of withdrawing furosemide in stable, euvolemic, chronic HF outpatients. This multicenter initiative is part of the Brazilian Research Network in Heart Failure (ReBIC) created to develop clinical studies in HF and composed predominantly by university tertiary care hospitals...
December 2017: American Heart Journal
https://www.readbyqxmd.com/read/29142756/usefulness-of-central-venous-saturation-as-a-predictor-of-thiamine-deficiency-in-critically-ill-patients-a-case-report
#8
Genri Numata, Satoshi Kodera, Hiroyuki Kiriyama, Atsuko Nakayama, Eisuke Amiya, Arihiro Kiyosue, Masaru Hatano, Eiki Takimoto, Masafumi Watanabe, Issei Komuro
Background: Central venous oxygen saturation (ScvO2) reflects the balance of oxygen delivery and consumption. Low ScvO2 indicates the presence of inadequate oxygen delivery, while high ScvO2 indicates reduced oxygen consumption and is sometimes associated with a high mortality rate in critically ill patients from dysoxia. Thiamine is an essential cofactor in cellular aerobic metabolism. Thiamine deficiency is more prevalent than was previously thought, and underlies severe conditions in critically ill patients...
2017: Journal of Intensive Care
https://www.readbyqxmd.com/read/29137066/a-coronary-artery-fistula-having-connection-between-2-coronary-arteries-and-the-left-ventricle-a-case-report
#9
Chang-Yeon Kim, Ji Yong Choi, Kee Sik Kim
RATIONALE: Cases of coronary artery fistula having a connection with the cardiac cavity are rare. Here, we report a case in which 2 coronary arteries empty into the left ventricular cavity together. PATIENT CONCERNS: A 63-year-old woman who was diagnosed as having hypertension 20 years prior presented with dyspnea. DIAGNOSES: The coronary angiography revealed coronary artery fistula. INTERVENTIONS: Chest X-ray showed pulmonary edema...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29105751/real-life-use-of-neurohormonal-antagonists-and-loop-diuretics-in-chronic-heart-failure-analysis-of-serial-biomarker-measurements-and-clinical-outcome
#10
Milos Brankovic, K Martijn Akkerhuis, Nick van Boven, Olivier Manintveld, Tjeerd Germans, Jasper Brugts, Kadir Caliskan, Victor Umans, Alina Constantinescu, Isabella Kardys
We determined the temporal effects of neurohormonal antagonists and loop diuretics on serially assessed (3-monthly) cardio-renal biomarkers, functional status, and clinical outcomes in 250 patients with chronic heart failure (CHF) with reduced ejection fraction. In blood, we measured NT-proBNP, troponin T, C-reactive protein, creatinine, cystatin C; in urine, N-acetyl-beta-d-glucosaminidase and kidney-injury-molecule-1. ACE-inhibitors/ARB were inversely associated with cardiac impairment, inflammation and renal tubular damage, but not with glomerular dysfunction...
November 6, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29063302/effects-of-tolvaptan-on-urine-output-in-hospitalized-heart-failure-patients-with-hypoalbuminemia-or-proteinuria
#11
Koji Takagi, Naoki Sato, Shiro Ishihara, Michiko Sone, Hideo Tokuyama, Kenji Nakama, Toshiya Omote, Arifumi Kikuchi, Masahiro Ishikawa, Kenichi Amitani, Naoto Takahashi, Yuji Maruyama, Hajime Imura, Wataru Shimizu
Hypoalbuminemia is an independent prognostic factor in hospitalization for heart failure (HHF). Hypoalbuminemia or proteinuria is related to resistance to loop diuretics. Tolvaptan is an oral non-peptide, competitive antagonist of vasopressin receptor-2. It has been used for the treatment of volume overload in HHF patients in several Asian countries. Several studies have demonstrated marked improvement in congestion in HHF patients. However, whether tolvaptan is useful for HHF patients with hypoalbuminemia or proteinuria (both of which are related to resistance to loop diuretics) has not been clarified...
October 23, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/29056238/value-of-routine-investigations-to-predict-loop-diuretic-down-titration-success-in-stable-heart-failure
#12
Pieter Martens, Frederik H Verbrugge, Levinia Boonen, Petra Nijst, Matthias Dupont, Wilfried Mullens
AIMS: Guidelines advocate down-titration of loop diuretics in chronic heart failure (CHF) when patients have no signs of volume overload. Limited data are available on the expected success rate of this practice or how routine diagnostic tests might help steering this process. METHODS AND RESULTS: Fifty ambulatory CHF-patients on stable neurohumoral blocker/diuretic therapy for at least 3months without any clinical sign of volume overload were prospectively included to undergo loop diuretic down-titration...
January 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29054185/the-prognostic-significance-of-serum-sodium-in-a-population-undergoing-cardiac-resynchronisation-therapy
#13
Kaushik Guha, Jens Spießhöfer, Adam Hartley, Simon Pearse, Philip Y Xiu, Rakesh Sharma
PURPOSE: To determine the prognostic implications of changes towards hyponatremia at varying time-points in the treatment of patients undergoing cardiac resynchronisation therapy (CRT). METHODS: A retrospective series of 249 patients was studied from 2002 to 2013. The population was categorized on the basis of serum sodium profile at baseline, at 1 month and at 6 month follow up visits following successful CRT implantation. The composite endpoint was all-cause mortality and heart failure hospitalisation (defined by the need for intravenous diuretic therapy) following CRT implantation...
September 2017: Indian Heart Journal
https://www.readbyqxmd.com/read/29042392/renal-and-cardiovascular-effects-of-sodium-glucose-cotransporter-2-sglt2-inhibition-in-combination-with-loop-diuretics-in-diabetic-patients-with-chronic-heart-failure-recede-chf-protocol-for-a-randomised-controlled-double-blind-cross-over-trial
#14
Natalie A Mordi, Ify R Mordi, Jagdeep S Singh, Fatima Baig, Anna-Maria Choy, Rory J McCrimmon, Allan D Struthers, Chim C Lang
INTRODUCTION: Type 2 diabetes (T2D) and heart failure (HF) are a frequent combination, where treatment options remain limited. There has been increasing interest around the sodium-glucose cotransporter 2 (SGLT2) inhibitors and their use in patients with HF. Data on the effect of SGLT2 inhibitor use with diuretics are limited. We hypothesise that SGLT2 inhibition may augment the effects of loop diuretics and the benefits of SGLT2 inhibitors may extend beyond those of their metabolic (glycaemic parameters and weight loss) and haemodynamic parameters...
October 16, 2017: BMJ Open
https://www.readbyqxmd.com/read/29039840/-use-of-loop-diuretics-in-heart-failure-current-aspects
#15
N V Kurlykina, E M Seredenina, Yа A Orlova
Loop diuretics take the lead in the treatment of patients with symptomatic heart failure. Torasemide is the most effective and safe loop diuretic with the optimal pharmacokinetic profile, the additional properties associated with simultaneous blockade of the renin-angiotensin-aldosterone system and with the antiadrenergic effects of the drug, its positive impact on myocardial fibrosis and minimal severe potential negative effects. Sustained-release torasemide provides a more comfortable removal of excess liquid and does not deteriorate quality of life...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/29024278/why-do-sglt2-inhibitors-reduce-heart-failure-hospitalization-a-differential-volume-regulation-hypothesis
#16
REVIEW
Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure. We hypothesize that osmotic diuresis induced by SGLT2 inhibition, a distinctly different diuretic mechanism than that of other diuretic classes, results in greater electrolyte-free water clearance and, ultimately, in greater fluid clearance from the interstitial fluid (IF) space than from the circulation, potentially resulting in congestion relief with minimal impact on blood volume, arterial filling and organ perfusion...
October 12, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29019614/associations-of-serum-potassium-levels-with-mortality-in-chronic-heart-failure-patients
#17
Mette Aldahl, Anne-Sofie Caroline Jensen, Line Davidsen, Matilde Alida Eriksen, Steen Møller Hansen, Berit Jamie Nielsen, Maria Lukács Krogager, Lars Køber, Christian Torp-Pedersen, Peter Søgaard
Aims: Medication prescribed to patients suffering from chronic heart failure carries an increased risk of impaired potassium homeostasis. We examined the relation between different levels of serum potassium and mortality among patients with chronic heart failure. Methods and results: From Danish National registries, we identified 19 549 patients with a chronic heart failure diagnosis who had a measurement of potassium within minimum 90 days after initiated medical treatment with loop diuretics and angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers...
October 7, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28982672/sodium-and-fluid-excretion-with-torsemide-in-healthy-subjects-is-limited-by-the-short-duration-of-diuretic-action
#18
Salim Shah, Bertram Pitt, D Craig Brater, Peter U Feig, Wen Shen, Fatima S Khwaja, Christopher S Wilcox
BACKGROUND: Loop diuretics are highly natriuretic but their short duration of action permits postdiuretic sodium retention, which limits salt loss unless dietary salt is severely restricted. We tested the hypothesis that a more prolonged duration of action would enhance salt loss. METHODS AND RESULTS: Ten healthy participants were crossed over between 20 mg of oral immediate-release or extended-release (ER) torsemide while consuming a fixed diet with 300 mmol·d(-1) of Na(+)...
October 5, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28980452/rationale-and-study-design-of-intravenous-loop-diuretic-administration-in-acute-heart-failure-diur-ahf
#19
Alberto Palazzuoli, Gaetano Ruocco, Giorgio Vescovo, Roberto Valle, Salvatore Di Somma, Ranuccio Nuti
AIMS: Although loop diuretics are the most commonly used drugs in acute heart failure (AHF) treatment, their short-term and long-term effects are relatively unknown. The significance of worsening renal function occurrence during intravenous treatment is not clear enough. This trial aims to clarify all these features and contemplate whether continuous infusion is better than an intermittent strategy in terms of decongestion efficacy, diuretic efficiency, renal function, and long-term prognosis...
October 4, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28975664/short-term-efficacy-and-safety-of-torasemide-and-furosemide-in-366-dogs-with-degenerative-mitral-valve-disease-the-test-study
#20
V Chetboul, J-L Pouchelon, J Menard, J Blanc, L Desquilbet, A Petit, S Rougier, L Lucats, F Woehrle
BACKGROUND: Furosemide is the only loop diuretic recommended by the ACVIM consensus guidelines for treatment of congestive heart failure (CHF) in dogs related to degenerative mitral valve disease (DMVD). Torasemide is another potent loop diuretic with a longer half-life and a higher bioavailability. OBJECTIVES: (1) To demonstrate that torasemide given once a day (q24h) is noninferior to furosemide given twice a day (q12h) for treating dogs with CHF; (2) and to compare the effect of the 2 drugs on the time to reach a composite cardiac endpoint "spontaneous cardiac death, euthanasia due to heart failure or CHF class worsening...
October 4, 2017: Journal of Veterinary Internal Medicine
keyword
keyword
112952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"